Belgian biotech Galapagos has abandoned its planned separation into two companies, citing unfavorable "regulatory and market conditions" that prompted a strategic reassessment.
Galapagos NV secured FDA IND clearance for GLPG5101, a CAR-T therapy, enabling U.S. patient recruitment for Phase II ATALANTA study in non-Hodgkin lymphoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.